The search for bioactive molecules in early-stage drug discovery using rapid compound screening and fragment-based design should not be like looking for a needle in a haystack. The collection is widely recognized for its market-leading diversity and quality. A highly diverse library of compounds that have the right chemical properties is much more likely to provide successful results than larger less diverse libraries with less suitable chemical properties.